Patent ID: 11919899
Assignee: nan
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 8:
9. The pharmaceutical composition according to claim 8, wherein the pharmaceutical composition is used for treatment of cancer, and wherein the compound of Formula (I) is administered simultaneously, separately or sequentially with at least one additional anti-tumor substance selected from the group consisting of cisplatin, oxaliplatin, carboplatin, valrubicin, idarubicin, doxorubicin, pirarubicin, irinotecan, topotecan, amrubicin, epirubicin, etoposide, mitomycin, bendamustine, chlorambucil, cyclophosphamide, ifosfamide, carmustine, melphalan, bleomycin, olaparib, rucaparib, niraparib, talazoparib, pamiparib, pembrolizumab, nivolumab, cemiplimab, spartalizumab, sintilimab, tislelizumab, dostarlimab, atezolizumab, avelumab, durvalumab, AZD1775, VX-970, BAY1895344 and AZD6738.